Fig 2: Comparison of tumor microenvironment features that mediated by OX40/0X40L in SCLC. (A–C) By the ESTIMATE algorithm, the differences of immune score, stromal score, and tumor purity between the high and low OX40 expression groups. (D–F) Comparison of immune score, stromal score, and tumor purity between the high and low OX40L expression groups. SCLC, small cell lung cancer; OX40L, OX40 ligand.

Fig 3: Estimation of relative infiltration proportions of 22 kinds of immune cells in the high and low OX40 expression group. (A) By the CIBERSORTx algorithm, relationship matrixes of 22 immune cells in small cell lung cancer patients wit h high and low OX40 expression. (B) The high OX40 expression group presented increased infiltration of 5 kinds of immune cells.

Fig 4: Estimation of relative infiltration proportions of 22 kinds of immune cells in the high and low OX40 ligand (OX40L) expression group. (A) By the CIBERSORTx algorithm, relationship matrixes of 22 immune cells in small cell lung cancer patients with high and low OX40L expression. (B) The infiltration of resting dendritic cells (p=O.OOO18) and activated memory CD4+ T cells (p=0.0018) was elevated in the hi OX40L group.

Fig 5: The biological functions and pathway enrichment of OX40L-related DEGs in SCLC. (A) A total of 3048 DEGs were identified between the high and low OX40L expression group. (B) The GO enrichment results of OX40L-related DEGs in SCLC. Go terms were divided into three types, including cellular component, biological process, and molecular function. (C) The KEGG enrichment results of OX40L-related DEGs in SCLC. DEGs, differentially expressed genes; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; SCLC, small cell lung cancer; OX40L, OX40 ligand.